A Phase 3 interventional study of Melatonin 5 mg in Attention Deficit Hyperactivity Disorder, sponsored by Hospital Israelita Albert Einstein. Status unknown at 1 site in Brazil. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-08-15.
Sponsored by Hospital Israelita Albert Einstein · Phase 3, Interventional, and Treatment
This study aims to evaluate the effect of melatonin supplementation as adjuvant treatment in ADHD in adults.
1,514 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 255 are open to participants now.
This study's planned enrollment of 120 is above the median of 72 across 1,206 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Browse Attention Deficit Disorder with Hyperactivity studies →Hospital Israelita Albert Einstein is the lead sponsor of 143 studies on the registry; 32 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Male and female age 18-60 inclusive. Primary diagnosis of ADHD AISRS total score ≥ 24 CGI-S ≥4 (moderately ill or worse). Understands and is able, willing, and likely to fully comply with the study procedures and restrictions.
Has given written informed consent to participate in the study.
Exclusion Criteria:
BMI less than18.5 or greater than 35. Any underlying/ history or current diagnosis of systemic and/or metabolic disease (e.g. diabetes, Crohn's disease) and/or neurological condition state that may render the subject illegible to participate in the study as assessed by medical history, physical exam, clinical and lab evaluation.
History of uncontrolled hypertension or a resting systolic blood pressure > 140mmHg or diastolic blood pressure > 90mmHg (Subjects with well controlled hypertension on a stable dose (2 months) of anti-hypertensives will be allowed to participate).
Major depression or anxiety disorder which is a focus of treatment or requires taking medication.
A lifetime history of psychosis or bipolar disorder Has any concurrent chronic or unstable medical condition that could confound with the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol.
Subjects taking any medication with CNS effects Subjects with a history of two or more prior failed adequate trials of ADHD treatment due to adverse events.
Use of dietary supplements with potential CNS effect, including omega-3 supplements, 30 days before study initiation and throughout the study.
Clinical history of cognitive impairment in judgment of investigator. Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed at screening visit prior to randomization. Women of childbearing potential must agree to use adequate birth control for the entire duration of the study.
Subjects with a current (within the last 3 months) DSM-V diagnosis of alcohol or drug abuse or dependence (excluding nicotine).
Has taken an investigational drug or taken part in a clinical trial within 30 days prior to screening.
Any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromise the subject safety.
Previous use of melatonin or melatonin analogues
Melatonin 5 mg taken 30 minutes before bed time
Drug: Melatonin 5 mg
Placebo identical to melatonin capsule taken 30 min before bed time
Drug: Melatonin 5 mg
Melatonin 5 mg taken 30 minutes before bed time
Also known as: Melatonina
Adult ADHD Investigator Symptom Rating Scale.
Each of the individual DSM-IV symptoms of ADHD is rated 0 to 3 on a scale of severity.
Time frame: 12 weeks
Anxiety
GAD-7 scale
Time frame: 12 weeks
Depression
PHQ-9 scale
Time frame: 12 weeks
CGI-S / I
Clinical Global Impression Severity / Improvement
Time frame: 12 weeks
Adverse Event Monitoring
Adverse Event Monitoring
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity→
Hospital Israelita Albert Einstein